Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 124   

Articles published

JNJ 101.27 -0.53 (-0.52%)
price chart
Johnson & Johnson Board Approves Additional $5 Billion Stock Buyback
Sales of a new hepatitis-C drug helped boost Johnson & Johnson's second-quarter revenue by 9%, but executives said they don't expect the pill's sales to keep pace, and outlined several challenges facing the overall health-care market last week.
Johnson & Johnson's $5 Billion Stock Buyback Approved  Bidness Etc
Health products maker Johnson & Johnson to buy back $5 billion worth of ...  Fox Business
Related articles »  
Johnson & Johnson Announces $5 Billion Share Repurchase Program
NEW BRUNSWICK, N.J., July 21, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has approved the repurchase of up to $5 billion of the company's common stock.
Johnson & Johnson (JNJ) Declares 70c Quarterly Dividend  TheStreet.com
Related articles »  
1 Key Way Obamacare Could Help Johnson & Johnson Stock
Johnson & Johnson's (NYSE: JNJ ) med device segment had a pretty sleepy first quarter, with 0.7% revenue growth (about 1% operationally).
Related articles »  
Regional Center Partnership Honors Johnson & Johnson for completion of river ...
The Somerset County Regional Center Partnership presented a unanimously passed resolution to representatives from Johnson & Johnson Information Technology (J&JIT) commemorating the recently awarded River-Friendly Certification for Business.
Johnson & Johnson's Results Boosted by Hepatitis C Drug
J&J's results benefited from rising sales of hepatitis C treatment Olysio, as well as consumer products such as baby wash.
Johnson & Johnson Profit Jumps 13% As Hepatitis Drugs Shine  Forbes
Johnson & Johnson Earnings Good News For Gilead Sciences  Barron's (blog)
Related articles »  
Johnson & Johnson sets $5 billion share buyback
SAN FRANCISCO (MarketWatch) -- Healthcare giant Johnson & Johnson (NYSE:JNJ) announced late Monday the company's board has approved a $5 billion buyback program of its common stock.
Johnson & Johnson CEO: No Plans to Leave US
Johnson & Johnson's strong second-quarter earnings are thanks to the company's focus on long-term goals, particularly in the pharmaceutical business, said CEO Alex Gorsky.
Johnson & Johnson CEO: Not Relocating Overseas  ValueWalk
Related articles »  
Johnson & Johnson Earnings: New Blockbuster Drug Olysio Lifts Sales But May ...
Johnson & Johnson recently released its second quarter results. While the company beat consensus estimates, its stock fell slightly due to a weaker-than-expected outlook for the second half of 2014.
Keep Calm and Carry On, J&J  Motley Fool
Related articles »  
Johnson & Johnson Popular Amongst Latest 13F Filers
At Holdings Channel, we have reviewed the latest batch of the 24 most recent 13-F filings for the 06/30/2014 reporting period, and noticed that Johnson & Johnson Johnson & Johnson (NYSE: JNJ) was held by 15 of these funds. When hedge fund managers ...
Johnson & Johnson Earnings Should Show Pharma Business To Remain Strong
Johnson & Johnson will report its Q2 2014 earnings on July 15. We expect no significant change in the intensity of the main trends driving the company's business.
Johnson & Johnson expecting strong Q2 EPS  IG
Related articles »